HK1121396A1 - Pqs and its conjugates as adjuvants and their uses in pharmaceutical compositions pqs - Google Patents

Pqs and its conjugates as adjuvants and their uses in pharmaceutical compositions pqs

Info

Publication number
HK1121396A1
HK1121396A1 HK09101781.2A HK09101781A HK1121396A1 HK 1121396 A1 HK1121396 A1 HK 1121396A1 HK 09101781 A HK09101781 A HK 09101781A HK 1121396 A1 HK1121396 A1 HK 1121396A1
Authority
HK
Hong Kong
Prior art keywords
pqs
conjugates
adjuvants
pharmaceutical compositions
pharmaceutical
Prior art date
Application number
HK09101781.2A
Other languages
English (en)
Inventor
Thomas Ebensen
Michael Morr
Carlos A Guzman
Original Assignee
Helmholtz Infektionsforschung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Infektionsforschung filed Critical Helmholtz Infektionsforschung
Publication of HK1121396A1 publication Critical patent/HK1121396A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
HK09101781.2A 2005-11-08 2009-02-25 Pqs and its conjugates as adjuvants and their uses in pharmaceutical compositions pqs HK1121396A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05024266A EP1782826A1 (en) 2005-11-08 2005-11-08 PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
PCT/EP2006/010699 WO2007054283A2 (en) 2005-11-08 2006-11-08 Pqs and its conjugates as adjuvants and their uses in pharmaceutical compositions

Publications (1)

Publication Number Publication Date
HK1121396A1 true HK1121396A1 (en) 2009-04-24

Family

ID=35840427

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09101781.2A HK1121396A1 (en) 2005-11-08 2009-02-25 Pqs and its conjugates as adjuvants and their uses in pharmaceutical compositions pqs

Country Status (7)

Country Link
US (2) US8257734B2 (xx)
EP (3) EP1782826A1 (xx)
AU (2) AU2006312688B2 (xx)
CA (2) CA2624905C (xx)
ES (1) ES2390895T3 (xx)
HK (1) HK1121396A1 (xx)
WO (2) WO2007054279A2 (xx)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1782826A1 (en) * 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
US9061048B2 (en) * 2010-12-15 2015-06-23 The Regents Of The University Of California Cyclic di-AMP induction of type I interferon
JP5650780B2 (ja) 2012-04-04 2015-01-07 日東電工株式会社 ワクチン組成物
EP2841098A4 (en) 2012-04-23 2016-03-02 Allertein Therapeutics Llc NANOPARTICLES FOR THE TREATMENT OF ALLERGIES
CA2876150A1 (en) 2012-06-08 2013-12-12 The Johns Hopkins University Compostions and methods for cancer immunotherapy
SG10201704611WA (en) 2012-12-13 2017-07-28 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
CN110201155A (zh) * 2012-12-19 2019-09-06 得克萨斯州立大学董事会 哺乳动物的环二核苷酸信号通路的药物靶向
EP2762160A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for mucosal administration
EP2762156A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Tape preparation of WT1 peptide cancer vaccine for transdermal administration
CA2841016A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for transdermal administration
JP6512567B2 (ja) 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用ｗｔ１ペプチド癌ワクチン組成物
US9840533B2 (en) * 2013-04-29 2017-12-12 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
EP2992000B1 (en) 2013-05-03 2020-07-08 The Regents of The University of California Cyclic di-nucleotide induction of type i interferon
PL2996473T3 (pl) * 2013-05-18 2020-06-01 Aduro Biotech, Inc. Kompozycje i sposoby aktywacji sygnałowania zależnego od „stymulatora genu interferonu”
CN105188373B (zh) * 2013-05-18 2017-09-22 艾杜罗生物科技公司 抑制“干扰素基因刺激蛋白”依赖性信号传导的组合物和方法
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
EP3027227A4 (en) 2013-07-31 2018-05-23 Memorial Sloan Kettering Cancer Center Sting crystals and modulators
WO2015074145A1 (en) 2013-11-22 2015-05-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
US20170101432A1 (en) 2014-03-03 2017-04-13 Yamasa Corporation Crystalline 3',5'-cyclic diguanylic acid
EP3118207B1 (en) * 2014-03-14 2020-08-05 Yamasa Corporation Inclusion compound of 3',5'-cyclicdiadenylic acid, and method for producing same
KR20170015353A (ko) 2014-06-04 2017-02-08 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Ｓｔｉｎｇ의 조절제로서 사이클릭 디­뉴클레오타이드
US10010607B2 (en) 2014-09-16 2018-07-03 Institut Curie Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
KR20170129802A (ko) * 2015-03-10 2017-11-27 아두로 바이오테크, 인코포레이티드 ＂인터페론 유전자의 자극인자＂-의존적 신호전달을 활성화하는 조성물 및 방법
MX2018001814A (es) 2015-08-13 2018-05-07 Merck Sharp & Dohme Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon.
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
PE20181297A1 (es) 2015-12-03 2018-08-07 Glaxosmithkline Ip Dev Ltd Dinucleotidos de purino ciclico como moduladores de sting
WO2017106740A1 (en) * 2015-12-16 2017-06-22 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production
JP6724156B2 (ja) 2016-03-16 2020-07-15 アンスティテュ・クリー 環状ジヌクレオチドを含むウイルス粒子を調製する方法及びがんを治療するための前記粒子の使用
CN109475570B (zh) 2016-03-18 2022-04-01 免疫传感器公司 环二核苷酸化合物及使用方法
IL285702B (en) 2016-04-07 2022-09-01 Glaxosmithkline Ip Dev Ltd Heterocyclic amides are useful as protein modulators
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
WO2017186711A1 (en) 2016-04-25 2017-11-02 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
US10696985B1 (en) 2016-06-06 2020-06-30 Vanderbilt University Reversibly crosslinked endosomolytic polymer vesicles for cytosolic drug delivery
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
US10300145B2 (en) 2016-07-15 2019-05-28 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
LT3523287T (lt) 2016-10-04 2021-11-10 Merck Sharp & Dohme Corp. Benzo[b]tiofeno junginiai, kaip sting agonistai
CA3038810A1 (en) 2016-10-11 2018-04-19 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
CN106928298B (zh) * 2017-03-13 2021-10-22 杭州星鳌生物科技有限公司 环二核苷酸cGAMP衍生物的结构组成、制备方法及其在抗肿瘤中的应用
CN118267470A (zh) 2017-04-13 2024-07-02 赛罗帕私人有限公司 抗SIRPα抗体
CA3058966A1 (en) 2017-04-14 2018-10-18 Tollnine, Inc. Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3621624B1 (en) 2017-05-12 2023-08-30 Merck Sharp & Dohme LLC Cyclic di-nucleotide compounds as sting agonists
WO2018232217A1 (en) 2017-06-16 2018-12-20 William Marsh Rice University Hydrogel delivery of sting immunotherapy for treatment of cancer
WO2019023459A1 (en) 2017-07-28 2019-01-31 Bristol-Myers Squibb Company CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
JP2020529421A (ja) 2017-08-04 2020-10-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がんの処置のためのＰＤ−１アンタゴニストおよびベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニストの組み合わせ
AU2018311966A1 (en) 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Benzo[b]thiophene sting agonists for cancer treatment
KR20200055037A (ko) 2017-09-19 2020-05-20 메사추세츠 인스티튜트 오브 테크놀로지 키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도
TW201927771A (zh) 2017-10-05 2019-07-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 可作為蛋白質調節劑之雜環醯胺及其使用方法
WO2019069275A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited STING AGONIST ADMINISTRATION METHODS
BR112020006780A2 (pt) 2017-10-05 2020-10-06 Glaxosmithkline Intellectual Property Development Limited moduladores do estimulador de genes do interferon (sting)
US11542293B2 (en) 2017-11-10 2023-01-03 Takeda Pharmaceutical Company Limited Sting modulator compounds, and methods of making and using
CN111566120B (zh) * 2017-12-20 2023-09-29 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
EP3727401A4 (en) 2017-12-20 2022-04-06 Merck Sharp & Dohme Corp. CYCLIC DINUCLEOTIDE COMPOUNDS USED AS STING AGONISTS
EP3737413A4 (en) * 2018-01-09 2021-12-15 N-Fold Llc IMMUNOMODULATION
JP7326319B2 (ja) 2018-04-03 2023-08-15 メルク・シャープ・アンド・ドーム・エルエルシー Ｓｔｉｎｇアゴニストとしてのベンゾチオフェン類及び関連する化合物
US11702430B2 (en) 2018-04-03 2023-07-18 Merck Sharp & Dohme Llc Aza-benzothiophene compounds as STING agonists
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
TW202019468A (zh) * 2018-08-03 2020-06-01 國立大學法人東京大學 誘導細胞性免疫之經鼻疫苗
MX2021001056A (es) 2018-08-13 2021-04-12 Alnylam Pharmaceuticals Inc Composiciones de agente de acido ribonucleico bicatenario (arnbc) de virus de la hepatitis b (vhb) y metodos de uso de las mismas.
WO2020049534A1 (en) 2018-09-07 2020-03-12 Novartis Ag Sting agonist and combination therapy thereof for the treatment of cancer
US20220008346A1 (en) 2018-10-30 2022-01-13 Vanderbilt University Graft copolymers, methods of forming graft copolymers, and methods of use thereof
TW202104214A (zh) 2019-04-05 2021-02-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 化合物
JP2022531899A (ja) 2019-05-09 2022-07-12 アリゴス セラピューティクス インコーポレイテッド Ｓｔｉｎｇモジュレータとしての修飾環状ジヌクレオシド化合物
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
TW202120551A (zh) 2019-08-12 2021-06-01 美商普瑞諾生物科技公司 藉由adcc靶向cd39表現細胞促進及增強t細胞介導免疫反應之方法及組合物
EP3785719A1 (en) * 2019-08-28 2021-03-03 Helmholtz-Zentrum für Infektionsforschung GmbH New use of cyclic dinucleotides
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
CN113058033B (zh) * 2019-12-16 2024-07-09 远大赛威信生命科学(南京)有限公司 一种用于预防和治疗乙型肝炎的药物组合物及其用途
CN115427458A (zh) 2020-02-28 2022-12-02 塔拉克治疗公司 转谷氨酰胺酶介导的缀合
WO2021198064A1 (en) * 2020-03-31 2021-10-07 Consejo Superior De Investigaciones Científicas In vitro method for detection of infections caused by pseudomonas aeruginosa
WO2021221783A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2021221782A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
EP3936514B1 (en) * 2020-07-10 2023-05-24 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with an alkenylene
EP4240488A1 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Antibody drug conjugates
JP2023554396A (ja) 2020-12-17 2023-12-27 トラスティーズ オブ タフツ カレッジ Ｆａｐ活性化ラジオセラノスティクスおよび関連する使用
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
EP4413038A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Pd-l1 binding affimers
WO2023168112A1 (en) 2022-03-04 2023-09-07 Massachusetts Institute Of Technology Transmucosal amphiphile-protein conjugate vaccine
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4948882A (en) * 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
DE3420116A1 (de) * 1984-05-30 1985-12-05 Bayer Ag, 5090 Leverkusen Immunstimulierende mittel
GB2257704B (en) * 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
AU3938893A (en) * 1992-03-27 1993-11-08 Abbott Laboratories Haptens, tracers, immunogens and antibodies for quinoline
EP1239923A2 (en) * 1999-12-20 2002-09-18 New Pharma Research Sweden AB Stabilized veterinary compositions comprising more than one antiviral agent
WO2002018342A2 (en) * 2000-08-31 2002-03-07 The University Of Iowa Research Foundation Novel autoinducer molecules and uses therefor
GB0030729D0 (en) * 2000-12-16 2001-01-31 Univ Nottingham Substituted-4-Quinolones
FR2822849B1 (fr) 2001-03-27 2003-12-12 Usinor Enceinte de traitement sous vide notamment de decarburation d'acier
GB0116312D0 (en) * 2001-07-04 2001-08-29 Univ Nottingham "Compositions containing N-acyl homoserine lactones"
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
DE50309916D1 (de) 2002-04-04 2008-07-10 Helmholtz Infektionsforschung Verwendung eines lipopeptids oder lipoproteins als adjuvans bei therapeutischer oder prophylaktischer vakzinierung
EP1382352A1 (de) 2002-07-19 2004-01-21 GBF Gesellschaft für Biotechnologische Forschung mbH Bisacyloxypropylcystein-Konjugate und deren Verwendung
DE10326303A1 (de) * 2003-06-11 2004-12-30 Celares Gmbh Reagenzien zur Modifikation von Biopharmazeutika, deren Herstellung und Anwendung
WO2005030186A2 (en) * 2003-07-28 2005-04-07 Univ Maryland Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
EP1729781B1 (en) * 2004-03-15 2012-10-24 Karaolis, David K. R. A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
EP1782826A1 (en) * 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions

Also Published As

Publication number Publication date
WO2007054279A2 (en) 2007-05-18
AU2006312688B2 (en) 2013-05-16
US20090169609A1 (en) 2009-07-02
EP1959989A2 (en) 2008-08-27
EP1782826A1 (en) 2007-05-09
US20080286296A1 (en) 2008-11-20
EP1959990B1 (en) 2012-07-18
AU2006312692A1 (en) 2007-05-18
EP1959990A2 (en) 2008-08-27
WO2007054279A8 (en) 2007-07-12
US9597391B2 (en) 2017-03-21
ES2390895T3 (es) 2012-11-19
EP1959989B1 (en) 2014-01-01
CA2624905C (en) 2015-04-28
WO2007054283A3 (en) 2007-08-09
US8257734B2 (en) 2012-09-04
CA2624903C (en) 2017-02-28
CA2624905A1 (en) 2007-05-18
WO2007054283A2 (en) 2007-05-18
WO2007054279A3 (en) 2007-08-30
AU2006312692B2 (en) 2013-05-02
AU2006312688A1 (en) 2007-05-18
CA2624903A1 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
HK1121396A1 (en) Pqs and its conjugates as adjuvants and their uses in pharmaceutical compositions pqs
IL194429A0 (en) Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
IL242883B (en) Aryl-amino and heteroaryl-amino converted deoxazolines and pharmaceutical preparations containing them
EP1890677A4 (en) PHARMACEUTICAL COMPOSITIONS AND THEIR USE
EP2056835A4 (en) PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
PL1883665T3 (pl) Kompozycje polilaktydowe i ich zastosowania
IL190292A (en) History of pyridopyrimidinone and their pharmaceutical preparations
GB0617191D0 (en) Improvements in pharmaceutical compositions
HK1112427A1 (en) Drug delivery compositions and related methods
IL180762A (en) Oligomer-insulin conjugates, formulations containing them and their use
HK1128871A1 (en) Pharmaceutical compositions comprising oxalate-reducing bacteria
SI2606874T1 (sl) Novi kozmetični in/ali farmacevtski sestavki in načini njihove uporabe
IL188352A0 (en) Pharmaceutical compositions
ZA200804163B (en) New adjuvants on the basis of bisacyloxypropylcysteine conjugates and derivatives and their uses in pharmaceutical compositions
IL205966A0 (en) Oligomer-tricyclic conjugates, compositions comprising the same and uses thereof
ZA200804103B (en) Pharmaceutical compositions
IL221395A0 (en) Pharmaceutical compositions comprising alpha ketoamide derivatives and uses thereof
EP1848438A4 (en) DIAMINOPHENOTHIAZINE COMPOSITIONS AND THEIR USE
HK1120436A1 (en) Hexosylceramides as adjuvants and their uses in pharmaceutical compositions
GB0614365D0 (en) Pharmaceutical compositions and their use
IL186337A0 (en) Stannsoporfin compositions and administration
IL192091A0 (en) Pharmaceutical compositions
EP1937292A4 (en) LOPAP-BASED PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
EP1845944A4 (en) PHARMACEUTICAL COMPOSITIONS
EP1865777A4 (en) STANNSOPORFIN COMPOSITIONS AND ADMINISTRATION

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20171108